Investor mix
5 investors on record.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 3 | 60% |
| Private equity | 2 | 40% |
Kinase inhibitors developing therapeutics for the treatment of serious eye conditions.
5 investors on record.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 3 | 60% |
| Private equity | 2 | 40% |